Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
about
The clinical utility of circulating tumour cells in patients with small cell lung cancer.Research in imaging/biomarkers for precision medicine in lung cancer: National Cancer Institute funding opportunities.Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer.Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer.Surgery for small cell lung cancer in the modern era: opportunities and challenges.The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer.[Concurrent once-daily or twice-daily chemoradiotherapy in limited-stage small-cell lung cancer?]Comparing Treatment Strategies for Stage I Small-cell lung Cancer.Current standards for clinical management of small cell lung cancer.Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy.Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't!No room for statins in the quest for survival benefits in small cell lung cancer.Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy.Impact of radiation dose on concurrent chemoradiotherapy for limited-stage small-cell lung cancer.Proton therapy for small cell lung cancer.Comparison and discussion of the treatment guidelines for small cell lung cancer.The evolving role of radiotherapy in the management of small cell lung cancer
P2860
Q41605002-0748EFDE-0643-4AB7-864B-4CEE2625B785Q47115640-C3E131A0-5008-4F72-ADAC-48A30ABA1FACQ47153324-5322B7BD-1146-416B-860A-02AC0165AC77Q47989130-E949492B-E797-4851-8DE6-94F97861E3BBQ49207460-A35FA40B-55B7-4688-ACFB-5C6EF3AFA5D3Q49886142-A17432C8-FC0F-4F92-9022-C2376F74FB12Q49978476-ADA2E6C3-9DD1-499D-86E5-7453F2203DEDQ52587549-7408B0A0-8D1E-44F6-894B-42266B9D64DDQ54953051-956224AF-0665-406E-9772-C8CAF0FFDA13Q55023905-E319AC72-00C1-464F-A4D2-70C9C1A19330Q55038620-606E6242-B075-448B-8F94-3C0DFA884526Q55062496-A0680A8F-302E-4587-BA3B-C65803FD9448Q55079973-47A9B7DC-AA51-4AB1-81AF-EF005DD0A824Q55093161-CFF60244-57A9-4D01-8376-898F07AD1D37Q55358944-D33FAEAB-42C6-4485-BEB8-27BEA9968271Q55516294-63738C70-3442-445F-823A-FD723AEAF086Q58804836-32053899-857D-4598-A395-B1558A1FD93E
P2860
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Concurrent once-daily versus t ...... randomised, superiority trial.
@en
type
label
Concurrent once-daily versus t ...... randomised, superiority trial.
@en
prefLabel
Concurrent once-daily versus t ...... randomised, superiority trial.
@en
P2093
P2860
P50
P1154
2-s2.0-85020944773
P1433
P1476
Concurrent once-daily versus t ...... randomised, superiority trial.
@en
P2093
Adityanarayan Bhatnagar
Andrea Bezjak
CONVERT Study Team
Cecile Le Pechoux
Fabrice Barlesi
Felipe Cardenal
Jan P Van Meerbeeck
Linda Ashcroft
Mary O'Brien
Michael Snee
P2860
P304
P356
10.1016/S1470-2045(17)30318-2
P5530
P577
2017-06-19T00:00:00Z
P6179
1086085229